You are here: Industry Insights > MEI Pharma

News List

MEI Pharma Announces Expansion of Zandelisib Phase 1b Study americanpharmaceuticalreview
January 11, 2021
MEI Pharma announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®) ...
MEI Pharma, KHK to develop and commercialize ME-401 biospectrumasia
November 26, 2018
MEI Pharma, Inc. and Kyowa Hakko Kirin Co., Ltd. (KHK), have announced the execution of a license agreement granting KHK exclusive rights to develop and commercialize ME-401 in Japan.
MEI Pharma, BeiGene to co-develop cancer drug biospectrum
October 15, 2018
Under the terms of the clinical collaboration agreement, MEI will amend its ongoing Phase 1b trial to include evaluation of ME-401 in combination with zanubrutinib in patients with B-cell malignancies
MEI Pharma, BeiGene Collaborate on ME-401, Zanubrutinib Combination americanpharmaceuticalreview
October 12, 2018
MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of pati
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scien biospace
December 22, 2017
New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma